The Daybue trial data results are valuable and it provided Acadia with FDA approval. I don't think it is wise to promote NNZ2591 for Rhett in the USA or anywhere else as it doesn't have the Rhett trial data to support it.
I am wondering if the NNZ2591 Angelman Trial results are positive, whether NEU will announce the other syndrome NEU is considering for this drug before it meets with the FDA in September 2024 - would make sense to raise the expanding potential of NNZ2591 with FDA at that point into time.
Ann: Trading Halt, page-33
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.99 |
Change
-0.030(0.23%) |
Mkt cap ! $1.664B | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.26 | $12.96 | $795.1K | 61.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 77 | $12.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.99 | 93 | 3 |
View Market Depth
| Last trade - 10.31am 15/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |